贝达药业(300558) - 2018 Q3 - 季度财报

Financial Performance - Operating revenue for the third quarter reached CNY 346,254,538.59, a year-on-year increase of 28.18%[7] - Net profit attributable to shareholders for the third quarter was CNY 81,086,597.52, up 22.22% year-on-year[7] - Basic earnings per share for the third quarter were CNY 0.20, reflecting a 17.65% increase compared to the same period last year[7] - The net profit attributable to shareholders for the year-to-date period decreased by 27.37% to CNY 147,759,399.95 due to increased R&D expenses and intangible asset amortization[7] - Total operating revenue for Q3 2018 reached ¥346,254,538.59, an increase of 28.2% compared to ¥270,136,038.23 in the same period last year[34] - Net profit for Q3 2018 reached CNY 81,743,710.70, up 28.8% from CNY 63,500,880.23 in Q3 2017[35] - The total comprehensive income for Q3 2018 was CNY 88,417,102.96, compared to CNY 56,331,055.15 in Q3 2017, indicating a growth of 57.0%[35] - The company's total profit for Q3 2018 was CNY 87,692,122.58, an increase of 11.8% from CNY 78,534,811.33 in the previous year[35] Assets and Liabilities - Total assets increased by 16.82% to CNY 3,239,400,773.92 compared to the end of the previous year[7] - Total assets as of the end of Q3 2018 amounted to ¥3,296,542,696.12, an increase from ¥2,721,976,818.92 at the beginning of the period[31] - Current assets totaled ¥1,196,084,830.07, up from ¥883,036,671.69 at the start of the year, indicating a growth of 35.5%[29] - The company's total liabilities reached ¥937,793,714.21, compared to ¥526,765,032.49 in the previous period, marking a 77.9% increase[31] - Long-term borrowings increased to ¥280,000,000.00 from ¥100,000,000.00, representing a 180% rise[31] Cash Flow - The company reported a net cash flow from operating activities of CNY 227,397,144.80, up 17.88% year-to-date[7] - Cash flow from financing activities rose by 215.67% to ¥313,343,667.72, reflecting an increase in bank loans[16] - Cash inflow from financing activities totaled $590 million, compared to $485 million in the prior period[51] - The net cash flow from financing activities was $110.03 million, an improvement from -$110.25 million in the previous period[51] - The cash and cash equivalents at the end of the period amounted to $256.85 million, down from $270.35 million in the prior period[51] Research and Development - Development expenditures surged by 68.81% to ¥468,972,448.99, reflecting increased capitalized spending on projects like MIL60 and CM082[16] - Research and development expenses for Q3 2018 were ¥67,986,988.19, an increase from ¥56,733,650.57 in the same quarter last year, indicating a focus on innovation[34] - Research and development expenses increased to CNY 58,709,966.50, up 30.5% from CNY 45,025,676.95 in the same quarter last year[36] - Research and development expenses increased to ¥161,815,069.34, up 31.99% from ¥122,582,184.99 in the previous period[43] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 19,137[10] - The top ten shareholders held a combined 66.77% of the company's shares, with the largest shareholder owning 19.97%[10] - The company distributed cash dividends of ¥60,150,000.00 based on a profit distribution plan approved in 2018[20] Inventory and Operating Costs - Inventory rose by 39.79% to ¥139,445,264.03 as a result of expanded sales and increased stocking for new production lines[16] - Operating costs grew by 30.32% to ¥41,975,213.85, driven by a substantial increase in sales volume[16] - Total operating costs for Q3 2018 were ¥275,904,994.31, up 31.5% from ¥209,710,138.38 in Q3 2017[34] - The total operating costs for Q3 2018 were CNY 15,679,947.33, up from CNY 10,177,373.60 in the same period last year, reflecting a growth of 54.0%[36] Clinical Trials and Product Pricing - The company is advancing clinical trials for new drugs Vorolanib (CM082) and JS001, which have been accepted by the National Medical Products Administration[18] - The company adjusted the price of its product, Erlotinib, from ¥1399 to ¥1345.05 per box, effective from July 2018[17]